Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

ANTI-HYPERTENSIVE DRUGS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Anti-Hypertensive Drugs in US$ Million. The report provides separate comprehensive analytics for US, Europe and Rest of World. Annual forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 145 companies including many key and niche players worldwide such as AstraZeneca PLC, AstraZeneca PLC, Biovail Corp, Biovail Corp, Biovail Corp, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Forest Laboratories, Inc., Forest Laboratories, Inc., Merck & Co., Inc., Mylan, Inc., Novartis AG,. Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi-aventis, Solvay Pharmaceuticals SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, and The Medicines Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code : MCP-6021
Price : $3950
Companies : 145
Pages : 893
Date : February 2010
Market Data Tables : 250

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  ANTI-HYPERTENSIVE DRUGS (Complete Report) Pages : 893   | $3950
 
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
II. EXECUTIVE SUMMARY66$2250
  1. MARKET AT A GLANCE.....II-13 $300  
   Introduction.....II-1
Hypertension – Prevalence.....II-1
Market Overview.....II-1
1$100
   Current and Future Analysis.....II-2
ARBs Lead the World Anti-hypertension Drugs Market.....II-2
1$100
   Lack of R&D Innovation, Genericization Characterize the Global Anti-Hypertensive Drugs
  Market.....II-3
1$100
  2. HYPERTENSION: Definition, Concerns, Consequences, Categorization, Diagnosis,
  Treatment, Side Effects, and Leading Drugs.....II-4
14 $900  
   Definition.....II-4
Blood Pressure.....II-4
High Blood Pressure.....II-4
Concerns.....II-4
1$100
   Consequences.....II-5
Hypertension and Diabetic Population.....II-5
Categorization.....II-5
Primary and Secondary Hypertension.....II-5
Acute Hypertension.....II-5
1$100
   Diagnosis.....II-6
Treatment.....II-6
Lifestyle Modifications.....II-6
Avoiding Nicotine Products.....II-6
Avoiding Alcohol.....II-6
Avoiding Processed Foods.....II-6
1$100
   Restricting Sodium.....II-7
Reducing Weight.....II-7
Adopting Biofeedback / Relaxation Techniques.....II-7
Anti-Hypertensive Drugs.....II-7
Beta Blockers.....II-7
1$100
   Types of Beta-blockers.....II-8
Calcium Channel Blockers.....II-8
Types of Calcium Channel Blockers.....II-8
Angiotensin II Receptor Blockers.....II-8
1$100
   Types of Angiotensin II Receptor Blockers.....II-9
ACE Inhibitors.....II-9
Types of ACE Inhibitors.....II-9
1$100
   Diuretics.....II-10
Types of Diuretics.....II-10
1$100
   Other Anti-hypertensive Drugs.....II-11
Renin Inhibitors.....II-11
Vasodilators.....II-11
Types of Vasodilators and Brand Names.....II-11
Alpha Blockers.....II-11
Mixed Blockers.....II-11
1$100
   Adrenergic Receptor Agonist.....II-12
Aldosterone Receptor Antagonists.....II-12
Central Alpha Agonists.....II-12
Side Effects.....II-12
Side Effects by Drug Class.....II-12
Thiazide Diuretics.....II-12
1$100
   Beta-blockers.....II-13
ACE Inhibitors.....II-13
Peripheral Vasodilators.....II-13
Side Effects by Drug Name.....II-13
Side Effects Profile of Select Anti-hypertensive Drugs.....II-13
2$200
   Select Leading Anti-hypertensive Drugs: A Review.....II-15
Benicar/Olmetec.....II-15
Cleviprex.....II-15
Cozaar.....II-15
Diovan/Diovan HCT.....II-15
1$100
   Exforge.....II-16
Norvasc.....II-16
Tekturna/Rasilez.....II-16
Tekturna HCT.....II-16
2$200
  3. RESEARCH & DEVELOPMENT.....II-185 $350  
   Takeda’s TAK-536 Reaches Phase III Clinical Trials in Japan.....II-18
China Pharma Commences Clinical Trials for Candesartan Generic.....II-18
Taipei Medical University Reveals Results of New Blood Pressure Study.....II-18
Researchers Identify New Genes Affecting Blood Pressure.....II-18
1$100
   Italian Study Demonstrates Benefits of Investigational Amlodipine and Telmisartan
  Combination Treatment in Blood Pressure Patients Exposed to Risk of Cardiovascular
    Events.....II-19
Gilead Sciences Announces Phase III Darusentan Data.....II-19
1$100
   Gilead Sciences Commences Phase II Trial of Cicletanine.....II-20
New Clinical Data Demonstrates Effectiveness of Rasilez/ Tekturna in Obese Patients
  with Hypertension in Comparison to Monotherapy with Diuretic
    Hydrochlorothiazide.....II-20
New Study Demonstrates Effectiveness of Exforge® in Controlling High Blood Pressure in
  "difficult-to-treat" Patients than Amlodipine Alone.....II-20
New Analyses Demonstrates Use of Cleviprex for Controlling Perioperative Hypertension
  to Lower the Risk of Heart Attack and Mortality Following Cardiac Surgery.....II-20
1$100
   Surface Logix Announces Encouraging Phase IIa Results of SLx-2101.....II-21
Observational Study Demonstrates Telmisartan to Provide Powerful Blood Pressure Control
  for Complete 24-hours, Including the Risky Hours of Early Morning.....II-21
1$100
   New Study Demonstrates Tekturna® When Combined with Diovan® to Have Additional Blood
  Pressure Lowering Effect.....II-22
Protherics Develops High Blood Pressure Vaccine.....II-22
1$100
  4. PRODUCT INTRODUCTIONS.....II-236 $400  
   Takeda Introduces ECARD for Hypertension Treatment.....II-23
Amneal Pharmaceuticals Introduces Benazepril HCI.....II-23
Ranbaxy Laboratories to Introduce Daiichi Sankyo's Olvance in India.....II-23
Gemini Pharmaceuticals Launches Anti-hypertensive Medicine, Micardis.....II-23
1$100
   Shionogi Introduces Fluitran® 1mg.....II-24
Helvepharm Launches New Anti-hypertensive Drug.....II-24
Ranbaxy Laboratories Introduces Amlodipine.....II-24
Nicholas Piramal Launches Hypertension Management Device.....II-24
GlaxoSmithKline Introduces Ambrisentan.....II-24
Novartis Introduces Aliskiren.....II-24
1$100
   Dainippon Introduces Avapro for Hypertension Treatment.....II-25
Shionogi Introduces Irbetan for Hypertension Treatment.....II-25
Pfizer Japan Introduces Sildenafil.....II-25
Surgipharm Launches Diovan and Co-diovan.....II-25
King Pharmaceuticals Introduces Altace Tablets.....II-25
Encysive Pharmaceuticals Introduces Thelin Tablets.....II-25
1$100
   Dr Reddy's Laboratories Introduces Atocor-R.....II-26
Wockhardt to Introduce Amlodipine Tablets.....II-26
GlaxoSmithKline Launches Coreg CR Extended-Release Capsules.....II-26
Toray and Astellas Introduce Careload LA Tablets.....II-26
Encysive Introduces Sitaxentan Encysive.....II-26
1$100
   GlaxoSmithKline Introduces Carzec.....II-27
Encysive Pharmaceuticals Introduces Thelin.....II-27
Ranbaxy Laboratories Introduces Generic Drug Verapamil.....II-27
Actavis Group Introduces NIFEdipine (XR) Tablets.....II-27
Apotex Introduces Norvasc Generic.....II-27
Novartis Introduces Aliskiren.....II-27
1$100
   Encysive Introduces Sitaxentan.....II-28
Pfizer to Release the Generic Version of Norvasc.....II-28
Mylan Introduces Generic Blood Pressure Medicines.....II-28
1$100
  5. RECENT INDUSTRY ACTIVITY.....II-2926 $1300  
   Sanofi-Aventis Takes Over Helvepharm.....II-29
ARCA Biopharma Merges with Nuvelo.....II-29
Astellas and Nippon Receive Approval for Micombi® Antihypertensive Drug.....II-29
The Medicines Co Announces EU Acceptance of MAA for Cleviprex.....II-29
1$100
   Actelion and GeneraMedix Sign Definitive Agreement.....II-30
AtCor Medical Enters into Contract with Pharmaceutical Company.....II-30
Ranbaxy Receives FDA Approval for Anti-hypertensive Drug .....II-30
Sun Pharmaceuticals Receives Approval for Generic Version of Accupril.....II-30
Sucampo Pharma Americas Wins Rights to Rescula.....II-30
1$100
   Novartis Obtains Approval from Japanese Health Ministry.....II-31
Novartis Obtains FDA Approval for Exforge HCT.....II-31
1$100
   Novartis Obtains Approval for Four New Medicines.....II-32
Aveva Drug Delivery Obtains Approval for Clonidine TDS.....II-32
Ranbaxy Receives Approval to Market Anti-Hypertension Drug .....II-32
Actelion Receives FDA Approval for New Ventavis Formulation.....II-32
Sinobiopharma Receives Chinese Approval for Perindopril.....II-32
1$100
   Pfizer Acquires Encysive Pharmaceuticals.....II-33
GlaxoSmithKline Acquires Bristol Myers Squibb’s Egyptian Business.....II-33
Gilead Sciences Acquires Navitas’ Cicletanine Business Assets.....II-33
1$100
   Shionogi Acquires Sciele Pharma.....II-34
Recordati Acquires Yeni Ilac.....II-34
Kyowa Hakko Merges with Kirin Pharma.....II-34
1$100
   Belupo and Farmavita Announce Merger.....II-35
Daiichi Sankyo India and GlaxoSmithKline Sign Co-Promotion Deal.....II-35
Sciele Pharma and Addrenex Pharmaceuticals Sign Exclusive Agreement.....II-35
Merck Serono Signs Distribution Agreement with Bristol-Myers Squibb.....II-35
1$100
   Forest Laboratories Holdings Amends Agreement with Mylan.....II-36
Speedel Secures FDA Approval for Tekturna HCT.....II-36
Lupin Receives FDA Approval for Generic Ramipril Capsules.....II-36
Daiichi Sankyo Submits Application for Anti-hypertensive Drug Approval.....II-36
1$100
   Mylan Receives FDA Approval for Nisoldipine Extended-Release.....II-37
Glenmark Wins FDA Approval for Trandolapril.....II-37
Novartis Obtains FDA Approval for Tekturna HCT.....II-37
Mylan Receives Tentative Approval for Generic Version of Benicar HCT.....II-37
Novartis Secures Swissmedic Approval for Rasilez HCT.....II-37
Kyowa Secures Japanese Approval for Amlodipine Generic.....II-37
1$100
   Aurobindo Pharma Obtains FDA Approval.....II-38
Actelion Receives EU Approval for Tracleer.....II-38
The Medicines Company Wins FDA Approval for Cleviprex.....II-38
Indian Pharmaceuticals Wins Approval for Propranolol Hydrochloride Tablets.....II-38
Aurobindo Pharma Secures FDA Approval for Lotensin Generic.....II-38
Zydus Cadila Obtains FDA Approval for Marketing of Benazepril.....II-38
1$100
   Mylan Wins FDA Approval for Mavik’s Generic.....II-39
Kampala Pharma to Commence Production of High Blood Pressure Drugs.....II-39
Merck Extends Licensing Agreement with AstraZeneca.....II-39
Helpson Receives China FDA Approval to Market Bumetanide Generic.....II-39
Sciele Pharma Obtains FDA Approval.....II-39
DAIICHI SANKYO ILAÇ Acquires Anti-hypertensive Drug, Concor.....II-39
1$100
   Novartis’ Rasilez HCT Receives European Committee Recommendation.....II-40
Pfizer Wins Patent Protection Lawsuit for Norvasc in Canada.....II-40
Forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion Agreement.....II-40
Novartis Wins Canadian Approval for Rasilez.....II-40
Hi-Tech Pharmacal Receives ANDA Approval from FDA.....II-40
1$100
   Dr. Reddy's Receives FDA Approval for Trandolapril.....II-41
Quantum Genomics and PCAS Pharma Sign Strategic Agreement.....II-41
GeneraMedix Wins Approval from FDA for Epoprostenol.....II-41
Pharmaceutical Holdings Changes Name to URL Pharma.....II-41
1$100
   Zydus Cadila Obtains Approval from U.S. FDA for Ramipril Capsules.....II-42
Zydus Cadila Obtains Approval from U.S. FDA for Four Drugs.....II-42
KV Pharmaceutical Obtains FDA Approval for Toprol-XL Generic.....II-42
Ranbaxy Pharmaceuticals and AstraZeneca Sign Agreements.....II-42
1$100
   Recordati Completes Mutual Recognition with 28 European Nations.....II-43
Recordati Obtains Australian Approval for Zan-Extra®.....II-43
Santen Pharmaceutical Obtains Approval for TAPROS.....II-43
Santen Obtains Marketing Authorization for TAFLOTAN.....II-43
1$100
   Boehringer Ingelheim Wins EU Commission Approval for MicardisPlus® 80/25.....II-44
Daiichi Sankyo Europe Obtains Marketing Approval of SEVIKAR®.....II-44
Daiichi Sankyo Establishes Subsidiary in Ireland.....II-44
GlaxoSmithKline Wins EC Marketing Approval for Volibris.....II-44
1$100
   NicOx Enters into Alliance with Royal DSM.....II-45
NicOx Enters into Alliance with Archimica.....II-45
NicOx Enters into Alliance with Capsugel.....II-45
Novartis Obtains FDA Approval for Exforge and Diovan HCT.....II-45
1$100
   Actelion and Merck Initiate Phase II Program Dosing, Reach Fourth Milestone.....II-46
Jupiter Bioscience Acquires Drug Technology.....II-46
Recordati- Berlin Chemie Expand Licensing Agreement.....II-46
Meda and Recordati Enter into Agreement for Zaneril®.....II-46
1$100
   Glenmark Wins FDA Approval for Coreg.....II-47
Novartis Secures FDA Approval for Exforge.....II-47
Caraco Receives ANDA Approval for Norvasc Generic.....II-47
Mylan and Forest Labs Win FDA Approval to Market Bystolic.....II-47
Daiichi Sankyo Secures FDA Approval for Azor.....II-47
1$100
   Teva Bags Approval to Market Accupril Generic.....II-48
Meda and Recordati Sign Long-Term Agreement.....II-48
Ranbaxy Bags Approval to Produce and Market Amlodipine Besylate.....II-48
Caraco Receives FDA Approval for Atenolol Tablets.....II-48
1$100
   Sciele Pharma and Addrenex Enter into Agreement.....II-49
Novartis Wins Swissmedic Approval for Tekturna.....II-49
Lupin Bags Approval to Market Prinivil’s Generic Version.....II-49
Aurobindo Pharma Receives FDA Approval for Accuretic’s Generic Version.....II-49
Gilead Sciences Wins FDA Approval for Letairis.....II-49
1$100
   Guangdong Luote Signs Agreement with Nippon Chemiphar.....II-50
Wockhardt Wins FDA Approval to Market Lisinopril.....II-50
Kaken to Commence Marketing Procylin for Pulmonary Hypertension Treatment.....II-50
Encysive Pharma Wins Australian Approval for THELIN®.....II-50
1$100
   Ranbaxy Wins Approval to Market Atenolol.....II-51
Novartis Secures EC Approval for Exforge.....II-51
Ranbaxy Receives Health Canada Approval for Lisinopril Tablets.....II-51
Ranbaxy Receives Tentative Approval for Valsartan Tablets.....II-51
1$100
   Bristol-Myers and sanofi-aventis Obtain FDA Approval for AVALIDE.....II-52
Par Pharmaceutical Receives FDA Approval for Propranolol HCl ER.....II-52
Ranbaxy Receives Approval from FDA for Coreg Generic.....II-52
1$100
   KV Pharmaceuticals Obtains FDA Approval for Toprol-XL Generic.....II-53
Mylan Wins Approval for Propranolol Hydrochloride ER Capsules.....II-53
Novartis Wins EU Approval for Rasilez.....II-53
Actavis Group Secures FDA Approval for Carvedilol Tablets.....II-53
Par Pharmaceuticals Ships ER Metoprolol Succinate Tablets.....II-53
1$100
   Biovail Reaches Settlement Agreement with Watson Pharmaceuticals.....II-54
Lexicon Genetics Announces Name Change.....II-54
1$100
  6. FOCUS ON SELECT MAJOR PLAYERS.....II-559 $600  
   AstraZeneca PLC (UK).....II-55
Bayer AG (Germany).....II-55
1$100
   Biovail Corp. (Canada).....II-56
Boehringer Ingelheim GmbH (Germany).....II-56
Bristol-Myers Squibb Company (USA).....II-56
1$100
   Daiichi Sankyo Company, Limited (Japan).....II-57
Dr. Reddy's Laboratories Ltd. (India).....II-57
Forest Laboratories, Inc. (USA).....II-57
1$100
   GlaxoSmithKline PLC (UK).....II-58
Merck & Co., Inc. (USA).....II-58
1$100
   Mylan, Inc. (USA).....II-59
Novartis AG (Switzerland).....II-59
1$100
   Pfizer, Inc. (USA).....II-60
Ranbaxy Laboratories Limited (India).....II-60
1$100
   Sanofi-aventis (France).....II-61
Solvay Pharmaceuticals SA (Belgium).....II-61
Takeda Pharmaceutical Company Limited (Japan).....II-61
1$100
   Teva Pharmaceutical Industries Limited (Israel).....II-62
The Medicines Company (USA).....II-62
2$200
  7. GLOBAL MARKET PERSPECTIVE.....II-64   
   Table 1: World Recent Past, Current & Future Analysis for Anti-hypertensive Drugs by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-641$300
   Table 2: World Historic Review Analysis for Anti-hypertensive Drugs by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-651$300
   Table 3: World 15-Year Perspective for Anti-hypertensive Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for the US, Europe and Rest of World Markets for 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-661$300
III. MARKET67$1950
  1. UNITED STATES.....III-128 $1675  
   A. Market Analysis.....III-1
Hypertension - Prevalence.....III-1
Table 4: Hypertension Prevalence Among Adults in the US – Percentage Share Breakdown by Age Group: 2005-2006 (includes corresponding Graph/Chart).....III-1
1$150
   Table 5: Hypertension Prevalence Among Adults in the US – Percentage Share Breakdown by Gender: 2005-2006.....III-2

Table 6: Hypertension Prevalence Among Adults in the US – Percentage Share Breakdown by Race/Ethnicity: 2005-2006 (includes corresponding Graph/Chart).....III-2

Table 7: Hypertension Treatment Among Hypertensive Adults in the US – Percentage Share Breakdown by Gender and Age Group: 2005-2006 (includes corresponding Graph/Chart).....III-2
1$150
   Table 8: Hypertension Treatment Among Hypertensive Adults in the US – Percentage Share Breakdown by Race/Ethnicity: 2005-2006 (includes corresponding Graph/Chart).....III-3

Table 9: Outpatient Department Visit with Hypertension as Co-morbid Chronic Condition in the US – Percentage Share Breakdown by Age Group: 2006 (includes corresponding Graph/Chart).....III-3
1$150
   Table 10: Outpatient Department Visits with Hypertension as Co-morbid Chronic Condition in the US – Percentage Share Breakdown by Gender: 2006.....III-4
Market Overview.....III-4
Table 11: US Anti-hypertensive Drugs Market – Sales and Percentage Share Breakdown by Leading Drugs in US$ Million Between October 2007 and October 2008 (includes corresponding Graph/Chart).....III-4
1$150
   Table 12: US Anti-hypertensive Drugs Market – Percentage Share Breakdown of Leading Class of Drug Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart).....III-5

Table 13: US Anti-hypertensive Drugs Market – Percentage Share Breakdown of ACE Inhibitors Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart).....III-5
1$150
   Table 14: US Anti-hypertensive Drugs Market – Percentage Share Breakdown of Angiotension Receptor Blockers (ARBs) Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart).....III-6
New Patient Therapy Starts to Witness Slowdown.....III-6
Table 15: US Anti-hypertensive Drugs Market – Percentage Share Breakdown of Angiotensin II Receptor Blockers by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart).....III-6
1$150
   Table 16: US Anti-hypertensive Drugs Market – Percentage Share Breakdown of ACE Inhibitors by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart).....III-71$150
   Table 17: US Anti-hypertensive Drugs Market – Percentage Share Breakdown of Calcium Channel Blockers by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart).....III-8
African Americans At Major Health Risk Due to Hypertension.....III-8
1$150
   Research & Development.....III-91$75
   Product Launches.....III-102$150
   Strategic Corporate Developments.....III-1213$675
   Select Players.....III-253$225
   B. Market Analytics.....III-28
Table 18: US Recent Past, Current & Future Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-28

Table 19: US Historic Review Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-28
1$150
  2. EUROPE.....III-2916 $875  
   A. Market Analysis.....III-29
Hypertension – Prevalence.....III-29
Non-Invasive Blood Pressure Monitoring on Growth Trajectory.....III-29
Regional Markets at a Glance.....III-29
United Kingdom.....III-29
Hypertension – Prevalence.....III-29
1$75
   Hypertension Treatment – Monotherapy and Combination Therapies.....III-30
Denmark.....III-30
Cheaper Alternatives for Hypertension Treatment.....III-30
Norway.....III-30
New Branded Drugs Dominate Anti-hypertensive Drugs Market.....III-30
New Amendments to Medicines Reimbursement.....III-30
1$75
   Proposed New Reimbursement Conditions in Norway.....III-311$75
   Research and Development.....III-322$150
   Product Launches.....III-341$75
   Strategic Corporate Developments.....III-355$375
   Select Players.....III-404$300
   B. Market Analytics.....III-44
Table 20: European Recent Past, Current & Future Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-44

Table 21: European Historic Review Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-44
1$150
  3. REST OF WORLD.....III-4523 $1450  
   A. Market Analysis.....III-45
Canada.....III-45
Table 22: Canadian Anti-hypertensive Drugs Market – Total Number of Prescriptions in Thousands for 1996 and 2006 (includes corresponding Graph/Chart).....III-45
1$150
   Japan.....III-46
Australia.....III-46
Australians to Shell Out More on Anti-Hypertensive Drugs.....III-46
China.....III-46
Hypertension – A Major Health Concern in China.....III-46
1$75
   Anti-hypertensive Drugs Market.....III-47
Hypertension Outlook.....III-47
1$75
   Competitive Landscape.....III-48
India.....III-48
Anti-Hypertensive Drugs Manufacturers.....III-48
Korea.....III-48
Anti-hypertensive Drugs Market.....III-48
1$75
   Table 23: Korean Anti-hypertensive Drugs Market – Leading Classes of Drugs by Value Sales in US$ Million for 2007, 2008, and 2009 (Q1) (includes corresponding Graph/Chart).....III-49

Table 24: Korean Anti-hypertensive Drugs Market – Percentage Share Breakdown of Leading Drugs by Outpatient Prescription Value for 2007, 2008 and 2009 (H1) (includes corresponding Graph/Chart).....III-49
1$150
   Anti-hypertension Drugs Market – Angiotensin Receptor Blockers.....III-50
Table 25: Korean Anti-hypertensive Drugs Market – Percentage Share Breakdown of Leading Angiotension Receptor Blockers by Prescription Value for 2008 and 2009 (Q1) (includes corresponding Graph/Chart).....III-50
1$150
   Anti-hypertension Drugs Market – Calcium Channel Blockers.....III-51
Table 26: Korean Anti-hypertensive Drugs Market – Percentage Share Breakdown of Leading Calcium Channel Blocker by Prescription Value for 2008 and 2009 (Q1) (includes corresponding Graph/Chart).....III-51
1$150
   Anti-hypertension Drugs Market – Beta-blockers.....III-52
Table 27: Korean Anti-hypertensive Drugs Market – Percentage Share Breakdown of Leading Beta- blockers for 2008 and 2009 (Q1) (includes corresponding Graph/Chart).....III-52
1$150
   Kenya.....III-53
Anti-hypertensive Drugs Market.....III-53
Manufacturing Overview.....III-53
Generics Erode Share of Ethical Drugs.....III-53
1$75
   Research and Development.....III-541$75
   Product Launches.....III-552$150
   Strategic Corporate Developments.....III-577$325
   Select Players.....III-643$225
   B. Market Analytics.....III-67
Table 28: Rest of World Recent Past, Current & Future Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-67

Table 29: Rest of World Historic Review Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-67
1$150
IV. COMPETITIVE LANDSCAPE 739$995
  
Total Companies Profiled: 145 (including Divisions/Subsidiaries - 176)

Region/Country                 Players


The United States                 31   
Canada                             4
Japan                             15
Europe                            51
     France                        7
     Germany                       6
     The United Kingdom            8
     Italy                         3
     Spain                         3
     Rest of Europe               24
Asia-Pacific (Excluding Japan)    65
Latin America                      2
Africa                             2
Middle East                        6
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign